Centessa Pharmaceuticals plc: The Big Acquisition Update

Centessa Pharmaceuticals (ticker: CNTA) has reached a major milestone in its path to becoming part of Eli Lilly and Company. Here is a breakdown of the recent shareholder vote and what the upcoming acquisition means for you.

1. What happened?

On June 12, 2026, Centessa held two vital meetings: a Court Meeting and a General Meeting. Shareholders voted to approve the "scheme of arrangement." This is the legal process required under U.K. law to complete the sale. The proposal passed with the necessary votes, giving the board the green light to move forward with the terms agreed upon with Eli Lilly.

2. Why is this happening?

Centessa is a drug-development company that does not yet make a profit. It spends heavily on research and development. By joining Eli Lilly, Centessa gains the massive financial resources and expertise it needs to grow. This partnership will help advance its pipeline of treatments for complex diseases that require large-scale manufacturing and sales power.

3. Why does this matter?

This deal is the result of Centessa’s long-term strategy. The successful vote removes the biggest uncertainty regarding whether the deal would actually happen.

• For Shareholders: The vote confirms you are on track to receive the agreed-upon cash payment for your shares.
• For the Industry: The deal proves the value of Centessa’s research platform. It shows that Eli Lilly is committed to growing its medicine portfolio by buying innovative companies.

4. Who is affected?

• Investors: Now that the vote is over, the focus shifts from clinical trial results to finishing the final legal and regulatory steps.
• Patients: The move aims to use Eli Lilly’s size to speed up the development and approval of Centessa’s experimental treatments.
• The Company: Centessa will stop being an independent, public company. Its American Depositary Shares (ADS) will be removed from the Nasdaq Global Market.

5. What happens next?

The deal still needs approval from the High Court of Justice in England and Wales. A judge must review the agreement. Once the court order is filed with the Registrar of Companies, the deal becomes official. At that point, the shares will be transferred to Eli Lilly.

6. What should investors/traders know?

• Price Convergence: As the deal nears the finish line, the price of CNTA shares will likely trade very close to the acquisition price. This small gap reflects the remaining time and minor risks until the deal closes.
• Final Closing: Once the deal is effective, your Centessa shares will be cancelled. You will then receive the cash payment promised in the merger agreement.
• Delisting: After the deal closes, Centessa will no longer be a public company. Keep an eye on future 8-K filings for the "Effective Date." That will be the final day you can trade CNTA shares.

Summary for your decision-making

If you are currently holding CNTA, the primary "event" (the shareholder vote) has passed. The remaining process is largely administrative. At this stage, the investment decision typically boils down to whether you want to wait for the final cash payout upon the deal’s closing or sell your shares now to free up capital for other opportunities.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and shouldn't be taken as professional investment advice. Always do your own research before making any trades!